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Case Report of Giant Nonmetastatic Gastrointestinal Solid Tumor without 
Clinical Manifestations in a Middle-Aged Male Patient 
I. Vynnychenko, M. Kononenko, O. Smorodska, S. Ivanov, Y. Moskalenko, 
O. Vynnychenko, V. Sikora, M. Lyndin, A. Romaniuk
Гастроинтестинальные стромальные опухоли (Гисо, GIST) – одни из наиболее часто встречаемых 
мезенхимальных опухолей, которые происходят из клеток Каяла. Наиболее часто встречающаяся локализа-
ция ГИСО – желудочно-кишечный тракт, однако иногда встречаются и внежелудочно-кишечные формы. 
Большинство ГИСО имеют малый размер, который чаще всего не превышает 5-8 см в максимальном из-
мерении. Данный клинический кейс описывает случай пациента с неметастатической гигантской опухолью 
желудка без каких-либо клинических проявлений. Опухоль была локализована в брюшной полости, зани-
мая почти всю ее, сдавливая и смещая окружающие органы. Ввиду кистозно-солидной структуры, ее ги-
гантских размеров и интимного прилегания к окружающим органам, провести точную дифференциальную 
диагностику до оперативного вмешательства не было возможно. Интраоперационная визуализация опу-
холи, дальнейшие гистологическое и иммуногистохимическое (CD117, CD34, S100, CD45, PanCK; Ki-67) 
исследования позволили установить диагноз ГИСО желудка T4N0M0, стадия II. На основании полученных 
данных, несмотря на гигантские размеры, прогноз заболевания был признан благоприятным (низкий ми-
тотический индекс, отсутствие метастазирования). За период клинического наблюдения, в течение 1,5 года 
после оперативного вмешательства, не было зарегистрировано рецидива или прогрессии заболевания, что 
говорит о благоприятном прогнозе для пациента.
Ключевые слова: опухоль желудка, гастроинтестинальная стромальная опухоль, гигантская опухоль, 
оперативное лечение
Gastrointestinal stromal tumors (GIST) are one of the most common mesenchymal tumors that originate 
from the intestinal cells of Cajal. The most common localization of GIST is the gastrointestinal tract, however, 
extragastrointestinal forms are sometimes found. Most GISTs are small in size, which most often does not exceed 
5 - 8 cm in maximum dimension. This article describes the case of a patient with a non-metastatic giant tumor 
of the stomach without any clinical manifestations. The tumor was localized in the abdominal cavity, occupying 
almost all of it, squeezing and displacing the surrounding organs. Due to the cystic-solid structure, its gigantic size 
and intimate adherence to the surrounding organs, it was not possible to carry out an accurate differential diagnosis 
before surgery. Intraoperative imaging of the tumor, further histological and immunohistochemical (CD117, CD34, 
S100, CD45, PanCK; Ki-67) studies made  possible to establish the diagnosis of gastric GIST T4N0M0 stage II. 
Based on the data obtained, despite the gigantic size, the prognosis of the disease was considered favorable (low 
mitotic index, no metastasis). During the period of clinical observation, within 1.5 years after surgery, no relapse or 
disease progression was recorded, which indicates a favorable prognosis for the patient.
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Introduction
Today, malignant tumors occupy one of the 
leading positions in the structure of mortality 
among the population. This pathology affects all 
tissues of a living organism and can be localized in 
various organs and tissues. The literature describes 
cases of extremely rare oncological diseases that 
can have difficult-to-predict treatment results [1]. 
Gastrointestinal stromal tumors (GIST) have a 
mesenchymal origin occured with a frequency of 
10-12-15-20 cases per 1 million people, the average 
age of patients is 60±2.9 years [2, 3, 4, 5]. GIST 
occurs much more frequently among the male 
population than among the female population. 
Tumors originate from intestinal cells of Cajal [6].
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The most common tumor localizations are: 
stomach (60-70%), small intestine (20-30%), colon 
and rectum (5%), esophagus (<5%); cases of GIST 
localization in the mesentery, omentum, extragas-
tric (so-called extra-gastrointestinal stromal tumors 
(EGIST)) were also described, although they can 
occur throughout the gastrointestinal tract [2, 3, 4, 
5, 7, 8]. GIST sizes are in the range of 1-2-30 cm, 
most often their size is <5-8 cm. About 20-30% of 
GISTs were discovered by accident, 10% of which 
were found during autopsy [6]. Approximately 80-
95% of these tumors contain the mutant form of 
the transmembrane tyrosine kinase receptor (Kit), 
5-7% contain platelet growth factor alpha recep-
tor (PDGFR№). The diagnostic markers of GIST 
when using the immunohistochemistry technique 
are CD117, DOG1 (11q13), theta PCK, CD34, 
desmin, SMA, S100 [4, 5, 6, 7, 8, 9, 10]. The 
tactics for treating such neoplasms are as follows: 
radical removal if the tumor is localized and has no 
metastases to regional lymph nodes. In the pres-
ence of metastases, tumor growth into neighboring 
structures, in addition to surgical treatment, targeted 
therapy with imatinibom mesylate (tyrosine kinase 
inhibitor) is used. If the tumor is resectable, surgical 
resection is the main choice of treatment regardless 
of location of the tumor, since complete resection 
can be performed in 85% of patients with primary 
disease [4, 6, 11, 12]. 
Radiofrequency ablation, as a method of treat-
ment, has shown its effectiveness in cases where sur-
gery is contraindicated or can not be performed.  [11].
Objective. To acquaint the medical community 
with a case of a rare disease having an unusual 
clinical course (giant non-metastatic GIST), the 
basics of its course and development, as well as the 
features of surgical treatment and morphological 
verification of the diagnosis.
A clinical case
In January 2019, a 57-year-old patient came 
to an appointment with complaints of abdominal 
distension. The symptom appeared after trying to 
lose weight, when, after increasing physical activity, 
he noted a reduction  in fat mass in all parts of 
the body except the abdomen, which retained its 
original size. The patient denied that he had ever 
used tobacco, alcohol or drugs. On admission, vital 
signs were normal, saturation was 96%. There were 
no concomitant diseases. On physical examination, 
the abdomen retained its shape and size regardless 
of the position of the patient. Lung examination 
revealed no abnormalities. The FBC and metabolic 
panel were unremarkable. Chest X-ray showed no 
abnormalities. Ultrasound examination showed 
a giant-sized cystic solid heterogeneous mass 
(29.5 x 22.0 x 24.0 cm), presumably derived 
from bursaomentalis, with a volume of about 8.0 
liters. Computed tomography (CT) with contrast 
in January 2019 revealed a tumor-like formation 
of giant sizes (35×32.3×18.7 cm), which has a 
mixed structure and consists of: a cystic-solid 
heterogeneous mass, septa and calcifications in 
the parenchyma, presumably originating from the 
omentum, comparable to the mesenchymoma , 
which occupied most of the abdominal cavity. The 
dense structure was found mainly in the cranial 
part of the formation. The formation squeezed 
and displaced the abdominal organs, as well as the 
retroperitoneal tissue. Metastases were not detected. 
Due to the structure of the tumor (a huge cystic 
component), it was decided not to perform a biopsy. 
Surgery with radical removal of the tumor 
was chosen as the method of treatment, so 
diagnostic studies did not reveal the obvious 
metastases to distant organs and regional lymph 
nodes. The operation was performed in February 
2019. The access – upper midline laparotomy. 
Intraoperative findings: the cystic component 
occupied most of the abdominal cavity; it was 
decided to evacuate 1/3 of the cyst volume in 
order to gain better access to the tumor. During the 
puncture, more than 3 liters of a yellow, cloudy, 
odorless liquid was obtained. Subsequently, the 
tumor was separated from the surrounding tissues 
and organs. The tumor had exophytic growth, a 
smooth capsule, which was covered with a large 
omentum on three sides (bottom and sides), and 
was located on the anterior wall of the stomach 
along the lesser curvature of the stomach  near the 
the angular notch, and was supplied with blood 
from the right gastric artery, while no blood supply 
from omental arteries. There were no technical 
difficulties during the operation, subserous 
resection of the tumor was performed, lymph 
dissection according to the recommendations of 
AJCC Cancer Staging Manual was not carried out.
Macroscopic description of the tumor: total 
weight – 12.0 kg (4.0 kg of solid component and 
8.0 kg of cystic contents), tumor was composed of 
4 cavities, that were different from each other (Fig. 
1). The tumor mass with multiple areas of necrosis 
and hemorrhage from the inner wall were revealed 
on cut surface. After the operation, biopsy with 
further histological examination was carried out, 
the morphological results of which corresponded 
to mesenchymal tumor and GIST.
Histological examination showed that the 
tumor was represented by elongated spindle-shaped 
cells with light cytoplasm, some of them had 
perinuclear clearing (vacuoles). 
An epithelioid cell component was found in a 
significantly smaller portion of the tumor. Among 
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the secondary changes in the tumor, the phenomena 
of pronounced myxomatosis, hemorrhages, foci of 
necrosis and hyalinosis were noted. Mitotic activity 
was low – less than 2 in 50 fields of view (Fig. 2).
To confirm the diagnosis, immunohistochemistry 
(IHC) was performed, which showed that tumor 
cells were negative for PanCK, CD45, S100, while 
CD117, CD34 were positive, the proliferation index 
(Ki-67 expression) was less than 5% (fig. 3). 
The morphological data corresponded to GIST 
with a combination of mixed (spindle-epithelioid) 
variant. Diagnosis: Gastric type of GIST T4N0M0 
stage II. Further observation within 18 months did 
not reveal changes, metastasis and local recurrence 
of the disease.
Gastrointestinal stromal tumors (GISTs) 
account for less than 1% of gastrointestinal tract 
(GI) tumors, but GIST is the most common 
mesenchymal tumor in all segments of the GI tract 
[2, 3, 4, 5]. Our patient's age is 57 years old, which 
correspons to the  general epidemiological data. He 
had the most common gastric GIST localization, 
but fortunately our patient was not included in 
a quarter of patients with metastatic disease and 
clinically aggressive disease.
It seems strange that a huge tumor did not have 
any clinical manifestations such as gastrointestinal 
bleeding, gastrointestinal obstruction, fatigue, 
dysphagia or chronic anemia, which are most 
common in this type of tumor [4, 5]. Computed 
tomography was used to diagnose and confirm GIST. 
Endoscopic ultrasound examination with fine needle 
aspiration biopsy was not performed to determine the 
type of tumor due to its exophytic growth and huge 
cystic component in order not to destroy the tumor 
and prevent its possible further spread. 
Open surgery remains the preferred procedure 
due to the size of the tumor and the huge cystic 
component, but laparoscopic surgery is the method 
of choice for tumors less than 5-10 cm. Histological 
study showed a combination of spindle-shaped and 
epithelioid variants, which is detected in only 10% 
of patients [10]. The final diagnosis was made only 
after positive expression of CD117 and CD34 had 
been revealed in tumor cells.
However, in this case, special attention should 
be paid to the molecular behavior of the tumor 
(mitotic activity, proliferation index, size and 
location, immune microenvironment, angiogenesis, 
etc.), which can be very helpful in choosing a 
treatment regimen [4, 7, 10,13].
Based on the data obtained, the patient has a 
moderate risk of disease progression – about 12% 
[14]. CT scan of the abdominal cavity / pelvic organs 
with an interval of 3 months was used as control 
studies and to monitor the patient's condition in the 
postoperative period. During the entire observation 
period, no relapse, local and distant metastases were 
detected, which, in turn, made it possible to judge 
a positive result of treatment.
Conclusion
The clinical picture of a gastrointestinal stromal 
tumor may be atypical, which greatly complicates 
the correct diagnosis. 
In the presented case, the final diagnosis was 
possible in case of comprehensive analysis of the 
results of instrumental diagnostics (ultrasound and 
CT), surgical intervention (tumor resection), his-
Fig. 1. Gastrointestinal stromal tumor of stomach.
Fig. 2. Gastrointestinal stromal  tumor of stomach. Hematoxylineand Eosinstaining.  Magnification: A ×40; B ×100; C ×400
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tological and immunohistochemical study: positive 
expression of CD117 and CD34; a Ki67 prolifera-
tion index less than 5%; negative expression of S100, 
CD45, PanCK. 
Morphological findings matched with GIST 
with a combination of mixed (spindle-epithelioid) 
variant. 
Diagnosis: Gastric type of GIST T4N0M0 
stage II. Within 18 months of observation, no re-
lapses and disease progression were recorded, which 
indicates a favorable prognosis for the patient.
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